Immortal Dragons Backs Renewal Bio to Grow Patient-Matched Cell PlatformSINGAPORE, SG / ACCESS Newswire / September 28, 2026 / Immortal Dragons, the $40 million purpose-driven longevity fund, today announced its strategic investment in Renewal Bio, an Israeli regenerative medicine company developing patient-matched human cells for transplantation. Renewal Bio was founded in 2022 as a spinout of the Weizmann Institute of Science. It is building its Stembroid™ platform to produce cells by harnessing the same developmental program that forms them naturally in the body.
Sundial Initiative Advisor Boyang Wang Sponsors Nakauchi Lab's Work on "Bodyoids"SINGAPORE, SG / ACCESS Newswire / July 30, 2026 / Boyang Wang, advisor to the Sundial Initiative and founder and CEO of the longevity fund Immortal Dragons, has sponsored the Nakauchi Lab, led by stem cell biologist Hiromitsu Nakauchi. The support is directed primarily at the lab's work on bodyoids.
